Search
BioCardia Inc
BCDAAdd to Watchlist
0.820USD
+0.049+6.35%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.97MMarket Cap
LossP/E TTM
More Details of BioCardia Inc Company
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
BioCardia Inc Info
Ticker SymbolBCDA
Company nameBioCardia Inc
IPO dateNov 13, 1996
CEOAltman (Peter)
Number of employees17
Security typeOrdinary Share
Fiscal year-endNov 13
Address320 Soquel Way
CitySUNNYVALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94085
Phone16502260123
Websitehttps://www.biocardia.com/
Ticker SymbolBCDA
IPO dateNov 13, 1996
CEOAltman (Peter)
Company Executives of BioCardia Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
764.27K
+14.29%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
638.74K
+0.42%
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
373.69K
-9.88%
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
114.25K
-20.24%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
--
Mr. Bill Facteau
Mr. Bill Facteau
Independent Director
Independent Director
13.12K
--
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Independent Director
Independent Director
3.62K
--
Mr. Edward Gillis
Mr. Edward Gillis
Senior Vice President - Devices
Senior Vice President - Devices
--
--
Mr. Marvin L. Slosman
Mr. Marvin L. Slosman
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
764.27K
+14.29%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
638.74K
+0.42%
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
373.69K
-9.88%
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
114.25K
-20.24%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
--
FAQs
Who are the top five shareholders of BioCardia Inc?
The top five shareholders of BioCardia Inc are: Dr. Simon H. Stertzer, M.D.
How many institutions hold shares of BioCardia Inc (BCDA)?
As of 2026Q1, 39 institutions hold shares of BioCardia Inc, with a combined market value of approximately 737.78K, accounting for 6.74% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 268093.00.